ClinicalTrials.gg
RecruitingNCT03912155SCALESUpdated Aug 6, 2024

Multi-scale Analysis of Physiological Brain Networks

An observational study in Epilepsy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Assistance Publique Hopitaux De Marseille · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2019; still recruiting 7 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille — 6 open to participants now, 7 under way, none of them phase 3. Epilepsy · Assistance Publique Hopitaux De Marseille.

Started
2019
with 1 other
Observational
3 of 18
3 open now
Registered
6th of 18
by date

Among the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, this one is one of 2 that started in 2019, is one of 3 observational ones, and was the 6th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

6 of the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, or all of them as a file.
02

Study summary

The SEEG implantation is performed on purely clinical criteria for preoperative diagnosis. Magnetoencephalography and EEG are purely passive techniques that do not involve any additional risk. This project is a continuation of an existing project in which it was demonstrated the feasibility of simultaneous SEEG and MEG/EEG recordings.

Read the detailed description

Brain function is based on the communication between sets of neurons at different spatial and temporal scales. The dysfunction of these networks is thus at the origin of several brain pathologies, including epilepsy. The recent improvement in recording methods paves the way for better characterization of brain networks, with several spatial and temporal resolutions, depending on the techniques used.

Still, several key points remain outstanding. First, several mechanisms can underlie the interaction between brain regions, and it remains to determine the most relevant tools in practice to quantify them. Second, there are difficulties in extracting these networks from surface recordings. The best strategies for studying these interactions in a non-invasive way therefore remain to be defined.

It will be propose to answer these questions based on simultaneous surface (magneto-encephalography/ electroencephalography) and depth (intracerebral stereotactic EEG, SEEG) recordings, a technique it was developed by the team of Marseille, in patients undergoing preoperative epilepsy assessment.

The primary objective is to find, among all the mechanisms of interaction between brain regions, which are most relevant in describing physiological and pathological brain networks.

The secondary objective is to test whether the visible coupling information at depth can be found from surface data (EEG, MEG) only. To do this, it will be compare the surface results with the SEEG results.

The SEEG implantation is performed on purely clinical criteria for preoperative diagnosis. Magnetoencephalography and EEG are purely passive techniques that do not involve any additional risk. This project is a continuation of an existing project in which we have demonstrated the feasibility of simultaneous SEEG and MEG/EEG recordings.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • MEG
  • EEG
  • SEEG
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The patients will be recruited in the Service of Epileptology and Cerebral Rhythmology of the Timone. Only major and minor control subjects will be recruited following the announcement of the experience by posting on different sites or other appropriate means of communication.

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria for patients

    • Patients for whom intracerebral electrode implantation is in progress as part of the pre-surgical evaluation of their drug-resistant partial epilepsy.
    • Patient informed, expressing his non-opposition (or legal representative (s), affiliated to a social security scheme
    • The medical examination is carried out as part of the medical follow-up of these patients
  • Inclusion criteria for control subjects

    • Informed subject, expressing his non-opposition or legal representative, affiliated to a social security scheme
  • Exclusion Criteria:

Minors under 12 years

  • Pregnant or lactating women,
  • The adults under guardianship or under the protection of justice
  • Non-beneficiaries of a social security scheme
  • Persons deprived of their liberty by a judicial or administrative decision
  • Absence of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Patients

    20 patients per presumed location of the epileptogenic zone (see experimental plan) for a total of 120 patients, including 30 minors. For patients, a MEG-EEG-SEEG examination during the SEEG exploration period.

    Other: Multi-scale analysis of physiological brain networks

  • Controles

    For the control population, 120 control subjects, including 30 minors, that is to say as many as patients. For control subjects, a MEG-EEG exam.

    Other: Multi-scale analysis of physiological brain networks

Interventions

  • OtherMulti-scale analysis of physiological brain networks

    It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.

06

What researchers measure

Primary outcomes

  1. Rate of epileptic discharges

    Measurement of epileptic activity by electroencephalogram

    Time frame: 2 hours

  2. Rate of epileptic discharges

    Measurement of epileptic activity by magneto-encephalography

    Time frame: 2 hours

  3. Rate of epileptic discharges

    Measurement of epileptic activity by intracerebral stereotactic electroencephalogram

    Time frame: 2 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Apr 2025, 72 months after the start.

Of 193 non-industry observational studies under Epilepsy, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 179. This study's planned 72 months is above that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 24 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2019
First posted
Apr 11, 2019
StartActual
Apr 15, 2019
Primary completionEst.
Apr 15, 2025
CompletionEst.
May 2, 2025
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03912155
Responsible party
Sponsor
First posted
Apr 11, 2019
Start date
Apr 15, 2019
Primary completion
Apr 15, 2025 (estimated)
Completion
May 2, 2025 (estimated)
Last update
Aug 6, 2024

Study contacts

Fabrice Bartolomei, PU-PH
Contact
fabrice.bartolomei@ap-hm.fr
491384995 ext. +33
Jean-Olivier ARNAUD, Director
study director · Assistance Publique Hôpitaux de Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion